TIME-2b Disappointed: Aerpio’s Lead Product Fails In Diabetic Retinopathy
As its lead product fails at Phase IIb in diabetic retinopathy, Aerpio’s attentions turn to its other potential indications, but investors will need more convincing that this strategy will pay dividends.
You may also be interested in...
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.